US Stock Market Move | Regencell Bioscience Holdings Ltd. (RGC.US) continues to surge over 29% in two trading days, accumulating nearly 400% increase.

On Tuesday, Regencell Bioscience Holdings Ltd. (RGC.US) continued to rise by over 29%, with a cumulative increase of nearly 400% over the past two trading days, closing at $77.30. On the news front, on May 9th, Regencell Bioscience Holdings Ltd. announced that its next-generation neural modulation chip had received FDA clinical trial approval, and will collaborate with the top global medical institution Mayo Clinic to conduct research on the treatment of Parkinson's disease. In addition, the company recently announced a 38-to-1 stock split, with the stock distribution scheduled for June 13, 2025, and trading of the split shares to begin on June 16, 2025. The purpose of the stock split is to enhance the liquidity of the company's common stock in the market and make shares more accessible to investors.